AR123724A1 - COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 - Google Patents
COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19Info
- Publication number
- AR123724A1 AR123724A1 ARP210102795A ARP210102795A AR123724A1 AR 123724 A1 AR123724 A1 AR 123724A1 AR P210102795 A ARP210102795 A AR P210102795A AR P210102795 A ARP210102795 A AR P210102795A AR 123724 A1 AR123724 A1 AR 123724A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- polynucleotide
- covid
- prevention
- compositions
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 3
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract 3
- 101710172711 Structural protein Proteins 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 229940096437 Protein S Drugs 0.000 abstract 1
- 108091007576 SARS-CoV-2 structural proteins Proteins 0.000 abstract 1
- 101710198474 Spike protein Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a composiciones y métodos para la preparación, la fabricación y el uso terapéutico de vacunas de ácido nucleico que comprenden secuencias de polinucleótidos que codifican una o más proteínas estructurales de SARS-CoV-2 y variantes para el tratamiento, la mitigación, la mejora y/o la prevención de la COVID-19. Reivindicación 1: Un polinucleótido que codifica al menos una proteína estructural de SARS-CoV-2 o una variante de esta, caracterizado porque al menos una proteína estructural es la proteína espicular (S) y donde el polinucleótido comprende una primera región de secuencia, dicha primera región de secuencia comprende una secuencia de ácido nucleico que tiene al menos un 80% de identidad con un miembro del grupo que consiste en las SEQ ID nº 7, 20, 26, 27 y 32. Reivindicación 13: Una vacuna de ácido nucleico caracterizada porque comprende el polinucleótido de la reivindicación 12. Reivindicación 15: Una composición farmacéutica caracterizada porque comprende la vacuna de ácido nucleico de la reivindicación 14 y un excipiente farmacéuticamente aceptable.The present disclosure relates to compositions and methods for the preparation, manufacture, and therapeutic use of nucleic acid vaccines comprising polynucleotide sequences encoding one or more SARS-CoV-2 structural proteins and variants for treatment, mitigation , improvement and/or prevention of COVID-19. Claim 1: A polynucleotide encoding at least one structural protein of SARS-CoV-2 or a variant thereof, characterized in that at least one structural protein is the spike protein (S) and where the polynucleotide comprises a first sequence region, said first sequence region comprises a nucleic acid sequence having at least 80% identity to a member of the group consisting of SEQ ID NOs: 7, 20, 26, 27 and 32. Claim 13: A characterized nucleic acid vaccine in that it comprises the polynucleotide of claim 12. Claim 15: A pharmaceutical composition characterized in that it comprises the nucleic acid vaccine of claim 14 and a pharmaceutically acceptable excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3096009A CA3096009A1 (en) | 2020-10-09 | 2020-10-09 | Compositions and methods for the prevention and/or treatment of covid-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123724A1 true AR123724A1 (en) | 2023-01-04 |
Family
ID=81077368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102795A AR123724A1 (en) | 2020-10-09 | 2021-10-07 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR123724A1 (en) |
| CA (2) | CA3096009A1 (en) |
-
2020
- 2020-10-09 CA CA3096009A patent/CA3096009A1/en not_active Abandoned
-
2021
- 2021-01-26 CA CA3107232A patent/CA3107232A1/en active Pending
- 2021-10-07 AR ARP210102795A patent/AR123724A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA3107232A1 (en) | 2022-04-09 |
| CA3096009A1 (en) | 2022-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107020A2 (en) | PCSK9 VACCINE (SUBTILISINE-KEXINA TYPE 9 CONVERTASE PROTEIN) | |
| RU2016146801A (en) | VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | |
| UY39060A (en) | COMPOSITIONS AND METHODS TO PREVENT AND TREAT CORONAVIRUS INFECTION - SARS-COV-2 VACCINES | |
| BR112022015626A2 (en) | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NEW CORONAVIRUS INFECTION | |
| MX2022015132A (en) | Nucleic acid based combination vaccines. | |
| MX2023000411A (en) | Sars-cov-2 and influenza combination vaccine. | |
| RU2012139432A (en) | Polypeptides | |
| SI2280721T1 (en) | IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| BRPI0610093A2 (en) | pharmaceutical composition, and method for preventing or treating a disease associated with alpha-beta amyloid deposits in a patient's brain | |
| MX2019003116A (en) | New swine influenza vaccine. | |
| PE20230171A1 (en) | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | |
| ATE103297T1 (en) | PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICINAL PREPARATION, A METHOD OF IMMUNIZING A MAMMAL AGAINST LHRH AND METHOD OF IMPROVING MEA. | |
| UY39464A (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | |
| AR127169A1 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | |
| ES2867049T3 (en) | Vaccine Compositions Comprising an Attenuated Mutant Zika Virus | |
| JP2024522385A5 (en) | ||
| AR123187A1 (en) | MULTI-EPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| AR088028A1 (en) | PROTEINS H5, FROM H5N1 FOR MEDICINAL USE | |
| AR095076A1 (en) | PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF ARTICULAR DAMAGE | |
| ES2868627T3 (en) | Genomic sequences encoding an attenuated mutant Zika virus | |
| AR123724A1 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | |
| AR100824A1 (en) | IMMUNOGENIC POLYPROTEIN COMPLEX OF M. HYOPNEUMONIAE, SYNTHETIC GEN CODIFYING OF THE IMMUNOGENIC PROLIPROTEIN COMPLEX OF M. HYOPNEUMONIAE, ANTIGENIC COMPOSITION, PROCESS OF OBTAINING A COMPLEX COMPLETION COMPLEX IN A BASE HYDRAULIC COMPLEX. IMMUNOGENIC OF M. HYOPNEUMONIAE | |
| AR112785A1 (en) | COMPOSITION OF PEPTIDES ASSOCIATED WITH PROLIFERATIVE TUMORS AND RELATED ANTI-CANCER IMMUNOGEN FOR THE TREATMENT OF LUNG CANCERS AND OTHER CANCERS | |
| AR133423A1 (en) | IBV VACCINE WITH HETEROLOGOUS DMV/1639 SPICLE PROTEIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |